Solventum Co. (NYSE:SOLV) Receives $68.29 Consensus Target Price from Analysts

Solventum Co. (NYSE:SOLV) has received a consensus recommendation of “Hold” from the eleven research firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and one has issued a buy recommendation on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $68.29.

Several research firms have recently commented on SOLV. BTIG Research started coverage on Solventum in a research note on Thursday, September 5th. They issued a “neutral” rating for the company. Stifel Nicolaus started coverage on Solventum in a research report on Tuesday, October 8th. They issued a “buy” rating and a $82.00 price objective for the company. Morgan Stanley boosted their price objective on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Wolfe Research initiated coverage on shares of Solventum in a research note on Thursday, September 26th. They issued a “peer perform” rating on the stock. Finally, Mizuho started coverage on shares of Solventum in a research note on Wednesday, December 4th. They set a “neutral” rating and a $70.00 price target for the company.

Institutional Investors Weigh In On Solventum

Large investors have recently bought and sold shares of the company. Worldquant Millennium Advisors LLC lifted its holdings in shares of Solventum by 373.6% during the 3rd quarter. Worldquant Millennium Advisors LLC now owns 47,665 shares of the company’s stock valued at $3,323,000 after purchasing an additional 37,600 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in Solventum by 37.4% in the third quarter. The Manufacturers Life Insurance Company now owns 117,853 shares of the company’s stock valued at $8,217,000 after buying an additional 32,051 shares in the last quarter. State Street Corp boosted its holdings in shares of Solventum by 3.1% in the third quarter. State Street Corp now owns 6,107,550 shares of the company’s stock valued at $425,818,000 after buying an additional 185,938 shares during the period. Point72 Asset Management L.P. acquired a new position in shares of Solventum in the third quarter valued at approximately $50,948,000. Finally, First Horizon Advisors Inc. acquired a new stake in shares of Solventum during the second quarter worth $58,000.

Solventum Trading Up 0.0 %

Shares of Solventum stock opened at $66.83 on Monday. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The firm has a 50 day simple moving average of $70.90 and a 200 day simple moving average of $63.50. Solventum has a fifty-two week low of $47.16 and a fifty-two week high of $96.05.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.